Navigation Links
Maxygen Reports Third Quarter 2007 Financial Results
Date:11/1/2007

h Roche to develop MAXY-VII for acute bleeding indications. MAXY-VII is a next-generation Factor VIIa, which Maxygen is currently developing for the treatment of hemophilia.

Research and development expenses for the quarter were $13.6 million compared to $12.0 million in the third quarter of 2006. The increase was primarily due to increased external expenses associated with the development of Maxygen's product candidates, including expenses related to conducting clinical trials and the manufacture of product for clinical trials.

At September 30, 2007, cash, cash equivalents and marketable securities totaled $157.1 million.

Conference Call Today

Maxygen will host a conference call to discuss its third quarter results today at 11:30 a.m. ET. Participants in the U.S. can access the call by dialing 800.561.2718 and using the passcode 15245655. International participants can dial 617.614.3525 and use the same passcode. A live webcast of the conference call will be available on the Maxygen web site at http://www.maxygen.com/webcasts.

Telephone and webcast replays of the conference call will be available for approximately 30 days. To access the telephone replay, dial 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 76932136. To access the webcast archive, go to http://www.maxygen.com/webcasts.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Our lead program, MAXY-G34, is designed to be an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Our preclinical pipeline includes a novel Factor VIIa for the treatment of hemophilia. Maxygen's approach to d
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... 03, 2015 , ... The Alexander Group, a 30-year old, ... alike-- typically known for its consummate professionalism-- embarks each year in a whacky ... from their day jobs. , "Our motto has always been work hard play ...
(Date:7/3/2015)... 2015  Pomerantz LLP announces that a class action ... or the "Company")(NYSE: PBYI ) and certain of ... District Court, Central District of California ... a class consisting of all persons or entities who ... 13, 2015 inclusive (the "Class Period").  This class action ...
(Date:7/2/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today announced a litigation update. ... Verizon Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, ... District of Virginia , the Court ... certain key claims in favor of the Defendants on ...
(Date:7/1/2015)... ... 01, 2015 , ... It is now possible to separate two common disorders: ... computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, ... and is believed to be the largest brain imaging study ever, will be published ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4
... European Partnerships, ALAMEDA, Calif., and PARIS, March ... Novartis Pharma AG to give Novartis,access to Singulex,s ... Program (ETAP). Terms of the collaboration,were not disclosed. ... a,facility in Paris, France to support the needs ...
... March 6 VaxGen,Inc. (Pink Sheets: VXGN), a biopharmaceutical ... recent cash balance, with a view to,ensuring that stockholders ... the company,s proposed merger with Raven biotechnologies,inc. VaxGen,s Board ... date for the,Special Meeting of Stockholders to vote on ...
... Conference call scheduled for March 13, 2008 at 1:30 p.m. (Pacific); ... simultaneous webcast at http://www.adventrx.com , ... today announced that it will host a conference call and,webcast on ... to discuss fourth quarter and year end 2007 results. Evan M.,Levine, ...
Cached Biology Technology:Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program 2VaxGen Reports Financial Update 2VaxGen Reports Financial Update 3VaxGen Reports Financial Update 4VaxGen Reports Financial Update 5VaxGen Reports Financial Update 6VaxGen Reports Financial Update 7
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... bring forth the best properties of both ever since ... Age. In the latest successful merger, researchers at the ... of Maryland (UM) and the U.S. Food and Drug ... substances that individually have generated interest for their potential ...
... SALT LAKE CITY An international consortium of researchers ... has reported that a study of nearly 2,300 people supports ... rare genetic changes called copy number variants (CNVs). The ... the Autism Genome Project (AGP), were published in Nature on ...
... - Researchers have discovered precisely why strands of some ... stretched, findings that could be used to improve industrial ... "Any kindergartner is familiar with this beading phenomenon, which ... between your thumb and forefinger," said Osman Basaran, Purdue,s ...
Cached Biology News:Liposome-hydrogel hybrids: No toil, no trouble for stronger bubbles 2Autism genome project identifies genetic variants that may make people susceptible to disorder 2Solution to beading-saliva mystery has practical purposes 2Solution to beading-saliva mystery has practical purposes 3
Inquire...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Biology Products: